The Week in Review: China Pledges $18 Billion for Biopharma 2011-2020
China plans to spend $11.8 billion to increase biopharma innovation in its 13th Five-Year Plan (2016-2020), bringing its ten-year total to over $18 billion; China Pharma Group paid $1.2 billion to acquire Robust Sun Holdings, which makes drugs for CNS diseases; Sinopharm Capital, Fosun Pharma and China Meheco will lead a $157 million PE fund for China biopharma; Cardinal Health added drug distribution coverage in China by acquiring Zhejiang Dasheng Medic; Zhejiang Medicine in-licensed China rights to manufacture and commercialize a broad-spectrum antibiotic from TaiGen Biotech of Taiwan; 3SBio received SFDA permission to conduct a Phase III trial of a anti-rejection drug; and PharmaNet/i3, a clinical-stage CRO, received the Distinguished Partner Award from the US Chinese Anti-Cancer Association. More details… Stock Symbols: (HK: 1093) (HK: 1099) (SHA: 600196) (SHA: 600056) (NYSE: CAH) (SHA: 600216) (NSDQ: SSRX) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here